37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
Iwata H, Im S, Sohn J, Jung K, Im Y, Lee K, Inoue K, Tamura K, Wong A, Emens L, Barrios C, Adams S, Schneeweiss A, Diéras V, Winer E, Chui S, Henschel V, Rugo H, Loi S, Schmid P. 37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries. Annals Of Oncology 2019, 30: ix13-ix14. DOI: 10.1093/annonc/mdz418.Peer-Reviewed Original ResearchTriple-negative breast cancerAdvanced triple-negative breast cancerGenentech/RochePD-L1 expressionPD-L1Bristol-Myers SquibbF. Hoffmann-La RocheDaiichi SankyoBoehringer IngelheimHoffmann-La RocheSeattle GeneticsRoche/GenentechTumor-infiltrating immune cellsBreast Cancer Research FoundationECOG PS 0Key secondary endpointPD-L1 positivityNew safety signalsPD-L1 testingCo-primary endpointsEli LillyCancer Research FoundationNational Cancer InstituteMedical writing assistanceMedical Research CouncilLBA20 Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios C, Iwata H, Dieras V, Winer E, Kockx M, Peeters D, Chui S, Lin J, Duc A, Viale G, Molinero L, Emens L. LBA20 Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Annals Of Oncology 2019, 30: v858-v859. DOI: 10.1093/annonc/mdz394.009.Peer-Reviewed Original ResearchF. Hoffmann-La Roche LtdBiomarker-evaluable populationGenentech/RocheOverall percentage agreementMetastatic triple-negative breast cancerPD-L1 statusPD-L1F. Hoffmann-La RocheBristol-Myers SquibbDaiichi SankyoPercentage agreementOS benefitHoffmann-La RocheRoche/GenentechEli LillyPD-L1 IHC assaysPD-L1 immunohistochemistry assaysIHC assaysBoehringer IngelheimBreast Cancer Research FoundationSeattle GeneticsTriple-negative breast cancerNegative percentage agreementGreater clinical benefitPositive percentage agreementLBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
Cortés J, Lipatov O, Im S, Gonçalves A, Lee K, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Zambelli S, Harbeck N, André F, Dent R, Zhou X, Karantza V, Mejia J, Winer E. LBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Annals Of Oncology 2019, 30: v859-v860. DOI: 10.1093/annonc/mdz394.010.Peer-Reviewed Original ResearchMetastatic triple-negative breast cancerCombined positive scoreSubsidiary of MerckGerman Study GroupDohme Corp.Merck SharpSeattle GeneticsGrade 3Study groupOpen-label phase III studyPD-L1 combined positive scoreEnd pointTriple-negative breast cancerDaiichi SankyoF. Hoffman-La RochePrior systemic treatmentPrimary end pointSecondary end pointsSingle-agent chemotherapyPhase III studyHigh-grade toxicityNegative breast cancerPD-L1 enrichmentTreatment effectsBristol-Myers Squibb